19:00-19:25 |
근거중심의 의학으로 본 최신 당뇨병 관리 키워드 노정현(인제의대) |
|
19:25-19:50 |
변화하는 당뇨 치료 트렌드 속 DPP4 억제제의 역할 김혜순(계명의대) |
|
19:00-20:00 |
Q&A |
19:00-19:25 |
SGLT-2 inhibitors as First-Line Therapy in Type 2 Diabetes 박정환(한양의대) |
|
19:25-19:50 |
Reno-protection from Sglt-2 inhibitors across the spectrum of risk 권민정(인제의대) |
|
19:50-20:00 |
Q&A |
19:00-19:25 |
Update on evidence-based management of high risk patients with hypertension 정수진(세종병원) |
|
19:25-19:50 |
Treatment of dyslipidemia in elderly patients with Osteoporosis, Sarcopenia & IFG 김경민(연세의대) |
|
19:50-20:00 |
Q&A |
19:00-19:25 |
Why? 제미+다파 (부제: 당뇨병 치료 로드맵 완성을 위한 최적의 조합 정지윤(순천향의대) |
|
19:25-19:50 |
Yes! 제미다파 (부제: 임상 데이터로 완성된 제미다파정) 박찬호(동아의대) |
|
19:50-20:00 |
Q&A |
12:15-12:30 |
What’s new? SGLT2 inhibitor's Enhanced glucose lowering effect - SGLT2 억제제의 향상된 혈당 강하 효과 임수(서울의대) |
|
12:30-12:45 |
Perspective in young T2DM patients: Pioglitazone 박세은(성균관의대) |
12:15-12:30 |
Management of T2DM patients using GLP-1 RA and Basal Insulin 김태년(인제의대) |
|
12:30-12:45 |
Cutting Edge Care of Pitavastatin with Ezetimibe Combination Therapy 전재한(경북의대) |
11:20-11:35 |
Paradigm shift in treatment of dyslipidemia 정인경(경희의대) |
|
11:35-11:50 |
Jardiance, Early treatment of T2D patients considering renal function 홍준화(을지의대) |
11:20-11:35 |
2023 ADA Guideline을 통해 알아보는 당뇨병 진료 유성훈(한양의대) |
|
11:35-11:50 |
Treatment Journey to Protect Bones from Fractures 최용준(아주의대) |
07:30-07:45 |
Glucose lowering Effect of DUVIE & Combination therapy with SGLT2-I 김진화(조선의대) |
|
07:45-08:00 |
Insight on the optimal diabetes care with new OW GLP-1RA in Asian patients 이용호(연세의대) |
07:30-07:45 |
Rationales for DPP-4i+SGLT-2i combination therapy for Holistic T2D Management 전윤경(부산의대) |
|
07:45-08:00 |
Exploring the benefits of Switching from other DPP-4 inhibitors to teneligliptin 김보현(부산의대) |